Your browser doesn't support javascript.
loading
The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
Arrieta-Bolaños, Esteban; Madrigal, J Alejandro; Marsh, Steven G E; Shaw, Bronwen E; Salazar-Sánchez, Lizbeth.
Afiliação
  • Arrieta-Bolaños E; Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London, UK; Cancer Institute, University College London, Royal Free Campus, London, UK; Centro de Investigaciones en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica. Electronic address: este
  • Madrigal JA; Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London, UK; Cancer Institute, University College London, Royal Free Campus, London, UK.
  • Marsh SG; Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London, UK; Cancer Institute, University College London, Royal Free Campus, London, UK.
  • Shaw BE; Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London, UK; Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Salazar-Sánchez L; Centro de Investigaciones en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica.
Hum Immunol ; 75(11): 1092-6, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25286002
HLA-B(∗)57:01 is a well-known and cost-effective pharmacogenetic marker for abacavir hypersensitivity. As with other HLA alleles, there is widespread variation in its frequency across populations. The Costa Rica Central Valley Population (CCVP) is the major population in this country. The frequency of HLA-B(∗)57:01 in this population has not been described yet. Thus, our aim was to determine the frequency of this allele in the CCVP. 200 unrelated healthy volunteer donors born in the CCVP were typed. HLA-B(∗)57-positive samples identified by HLA intermediate resolution typing methods were further typed by SBT to high resolution. An HLA-B(∗)57:01 carrier frequency of 5.00% was determined in this sample. This frequency is relatively high in comparison to reports from other populations in Latin America. These results suggest that there is a considerable frequency of HLA-B(∗)57:01 in the CCVP and that pharmacogenetic testing for HIV+ patients who are going to receive abacavir-based treatment should be considered in this country.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos HLA-B / Hipersensibilidade a Drogas / Frequência do Gene / Heterozigoto Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America central / Costa rica Idioma: En Revista: Hum Immunol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos HLA-B / Hipersensibilidade a Drogas / Frequência do Gene / Heterozigoto Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America central / Costa rica Idioma: En Revista: Hum Immunol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos